These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 630909)

  • 21. Long-term efficacy of fenfluramine in treatment of obesity.
    Douglas JG; Gough J; Preston PG; Frazer I; Haslett C; Chalmers SR; Munro JF
    Lancet; 1983 Feb; 1(8321):384-6. PubMed ID: 6130379
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of the efficacy and acceptability of fenfluramine tablets (BP) and prolonged action capsules.
    Innes JA; Campbell IW; Millar J; Munro JF
    Postgrad Med J; 1975; 51 Suppl 1():160-2. PubMed ID: 768961
    [No Abstract]   [Full Text] [Related]  

  • 23. Effects of dexfenfluramine on resting metabolic rate and thermogenesis in premenopausal obese women during therapeutic weight reduction.
    Van Gaal LF; Vansant GA; Steijaert MC; De Leeuw IH
    Metabolism; 1995 Feb; 44(2 Suppl 2):42-5. PubMed ID: 7869937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term weight control study. IV (weeks 156 to 190). The second double-blind phase.
    Weintraub M; Sundaresan PR; Schuster B; Averbuch M; Stein EC; Cox C; Byrne L
    Clin Pharmacol Ther; 1992 May; 51(5):608-14. PubMed ID: 1587075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dexfenfluramine in obese Chinese NIDDM patients. A placebo-controlled investigation of the effects on body weight, glycemic control, and cardiovascular risk factors.
    Chow CC; Ko GT; Tsang LW; Yeung VT; Chan JC; Cockram CS
    Diabetes Care; 1997 Jul; 20(7):1122-7. PubMed ID: 9203448
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fenfluramine, vitamin C and weight loss.
    Wilson CW; Foran K; Innes JA; Watson ML; Ford MJ; Stoddart ME; Munro JF
    Int J Obes; 1978; 2(4):463-5. PubMed ID: 370042
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo.
    Pontiroli AE; Pacchioni M; Piatti PM; Cassisa C; Camisasca R; Pozza G
    J Clin Endocrinol Metab; 1996 Oct; 81(10):3727-32. PubMed ID: 8855830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. International trial of long-term dexfenfluramine in obesity.
    Guy-Grand B; Apfelbaum M; Crepaldi G; Gries A; Lefebvre P; Turner P
    Lancet; 1989 Nov; 2(8672):1142-5. PubMed ID: 2572857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic effects of fenfluramine in obese diabetics.
    Larsen S; Vejtorp L; Hornnes P; Bechgaard H; Sestoft L; Lyngsoe J
    Br J Clin Pharmacol; 1977 Oct; 4(5):529-33. PubMed ID: 334212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo.
    Weintraub M; Sundaresan PR; Madan M; Schuster B; Balder A; Lasagna L; Cox C
    Clin Pharmacol Ther; 1992 May; 51(5):586-94. PubMed ID: 1587072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A clinical trial of a new fenfluramine preparation (Ponderax PA).
    Hooper AC
    Postgrad Med J; 1975; 51 Suppl 1():159-60. PubMed ID: 768960
    [No Abstract]   [Full Text] [Related]  

  • 32. [Efficacy and safety of dexfenfluramine treatment in obese adolescents].
    Małecka-Tendera E; Koehler B; Muchacka M; Wazowski R; Trzciakowska A
    Pediatr Pol; 1996 May; 71(5):431-6. PubMed ID: 8710426
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise.
    Weintraub M; Sundaresan PR; Schuster B; Ginsberg G; Madan M; Balder A; Stein EC; Byrne L
    Clin Pharmacol Ther; 1992 May; 51(5):595-601. PubMed ID: 1587073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dexfenfluramine as adjuvant to a low-calorie formula diet in the treatment of obesity: a randomized clinical trial.
    Andersen T; Astrup A; Quaade F
    Int J Obes Relat Metab Disord; 1992 Jan; 16(1):35-40. PubMed ID: 1314242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of a low-calorie diet with and without fenfluramine on the glucose tolerance and insulin secretion of obese maturity-onset diabetics.
    Dykes JR
    Postgrad Med J; 1973 May; 49(571):318-24. PubMed ID: 4804456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prolonged weight loss with dexfenfluramine treatment in obese patients.
    Finer N; Craddock D; Lavielle R; Keen H
    Diabete Metab; 1987; 13(6):598-602. PubMed ID: 3329122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fenfluramine therapy in non-insulin-dependent diabetic patients: effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.
    Salmela PI; Sotaniemi EA; Viikari J; Solakivi-Jaakkola T; Järvensivu P
    Diabetes Care; 1981; 4(5):535-40. PubMed ID: 6751729
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effect of dexfenfluramine on eating behavior and body weight of obese patients: results of a field study of Isomeride in Austrian general practice].
    Geyer G; Haidinger G; Francesconi M; Langmayr N; Prager R; Schoberberger R; Toplak H; von Kalckreuth G; Kunze M
    Acta Med Austriaca; 1995; 22(5):95-101; 104-9. PubMed ID: 8651045
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of prolonged fenfluramine administration in obese and nonobese mice.
    Carr RH; Ipaktchi M; Thenen SW
    Proc Soc Exp Biol Med; 1977 Jan; 154(1):116-20. PubMed ID: 320596
    [No Abstract]   [Full Text] [Related]  

  • 40. Metabolic effects of fenfluramine--a double-blind study.
    Petrie JC; Mowat JA; Bewsher PD; Stowers JM
    Postgrad Med J; 1975; 51 Suppl 1():139-44. PubMed ID: 768954
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.